Emergent Biosolutions (0IGA) Ratios
Emergent Biosolutions Ratios
GB:0IGA's free cash flow for Q2 2026 was $54.00M. For the 2026 fiscal year, GB:0IGA's free cash flow was decreased by $-2.10M and operating cash flow was $56.10M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.01 | 3.69 | 1.04 | 0.98 | 3.40 |
| Quick Ratio | 2.41 | 1.77 | 0.54 | 0.70 | 2.47 |
| Cash Ratio | 1.55 | 0.61 | 0.17 | 0.52 | 1.54 |
| Solvency Ratio | 0.19 | -0.09 | -0.54 | -0.05 | 0.25 |
| Operating Cash Flow Ratio | 1.29 | 0.36 | -0.32 | -0.03 | 0.86 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 21.74 | -0.50 | -0.04 | 8.59 |
| Net Current Asset Value | $ -133.50M | $ -308.20M | $ -494.40M | $ -568.20M | $ -76.30M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.43 | 0.49 | 0.47 | 0.45 | 0.29 |
| Debt-to-Equity Ratio | 1.09 | 1.40 | 1.32 | 1.03 | 0.54 |
| Debt-to-Capital Ratio | 0.52 | 0.58 | 0.57 | 0.51 | 0.35 |
| Long-Term Debt-to-Capital Ratio | 0.52 | 0.58 | 0.41 | 0.24 | 0.33 |
| Financial Leverage Ratio | 2.52 | 2.88 | 2.81 | 2.28 | 1.84 |
| Debt Service Coverage Ratio | 3.50 | 0.08 | -0.15 | 0.02 | 5.85 |
| Interest Coverage Ratio | 1.86 | -1.53 | -8.26 | -4.56 | 9.90 |
| Debt to Market Cap | 0.87 | 1.32 | 7.00 | 2.39 | 0.36 |
| Interest Debt Per Share | 11.80 | 14.10 | 18.52 | 29.22 | 16.93 |
| Net Debt to EBITDA | 1.54 | 10.80 | -15.93 | 49.92 | 0.58 |
| Profitability Margins | |||||
| Gross Profit Margin | 47.19% | 35.97% | 34.31% | 42.33% | 44.72% |
| EBIT Margin | 19.13% | -5.00% | -16.02% | -9.78% | 21.76% |
| EBITDA Margin | 32.02% | 5.12% | -4.48% | 1.40% | 28.43% |
| Operating Profit Margin | 14.83% | -10.42% | -69.23% | -15.21% | 19.25% |
| Pretax Profit Margin | 11.15% | -13.69% | -69.68% | -19.60% | 17.10% |
| Net Profit Margin | 7.08% | -18.26% | -72.48% | -18.94% | 12.38% |
| Continuous Operations Profit Margin | 7.08% | -18.26% | -72.48% | -18.94% | 12.38% |
| Net Income Per EBT | 63.53% | 133.38% | 104.01% | 96.62% | 72.39% |
| EBT Per EBIT | 75.14% | 131.46% | 100.66% | 128.82% | 88.81% |
| Return on Assets (ROA) | 3.99% | -13.72% | -41.71% | -6.68% | 7.42% |
| Return on Equity (ROE) | 10.07% | -39.48% | -117.13% | -15.25% | 13.62% |
| Return on Capital Employed (ROCE) | 9.29% | -8.86% | -61.98% | -8.77% | 13.21% |
| Return on Invested Capital (ROIC) | 5.90% | -8.84% | -45.81% | -5.66% | 9.43% |
| Return on Tangible Assets | 5.96% | -21.46% | -60.52% | -9.53% | 10.31% |
| Earnings Yield | 7.95% | -37.62% | -618.90% | -35.76% | 9.44% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.82 | 6.75 | 5.49 | 7.02 | 6.36 |
| Payables Turnover | 7.06 | 10.97 | 6.14 | 6.23 | 7.61 |
| Inventory Turnover | 1.14 | 2.14 | 2.10 | 1.84 | 2.85 |
| Fixed Asset Turnover | 3.62 | 3.86 | 2.63 | 1.34 | 2.14 |
| Asset Turnover | 0.56 | 0.75 | 0.58 | 0.35 | 0.60 |
| Working Capital Turnover Ratio | 1.54 | 4.49 | 216.35 | 2.55 | 2.08 |
| Cash Conversion Cycle | 309.14 | 191.03 | 181.19 | 192.00 | 137.66 |
| Days of Sales Outstanding | 41.37 | 54.04 | 66.44 | 52.00 | 57.40 |
| Days of Inventory Outstanding | 319.50 | 170.26 | 174.16 | 198.61 | 128.26 |
| Days of Payables Outstanding | 51.73 | 33.27 | 59.41 | 58.62 | 47.99 |
| Operating Cycle | 360.87 | 224.30 | 240.60 | 250.61 | 185.65 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.19 | 1.11 | -4.03 | -0.68 | 6.00 |
| Free Cash Flow Per Share | 2.93 | 0.68 | -5.04 | -2.99 | 1.80 |
| Dividend Paid and CapEx Coverage Ratio | 12.36 | 2.56 | -4.00 | -0.29 | 1.43 |
| Capital Expenditure Coverage Ratio | 12.36 | 2.56 | -4.00 | -0.29 | 1.43 |
| Operating Cash Flow Coverage Ratio | 0.30 | 0.09 | -0.24 | -0.02 | 0.37 |
| Operating Cash Flow to Sales Ratio | 0.23 | 0.06 | -0.20 | -0.03 | 0.18 |
| Free Cash Flow Yield | 23.71% | 7.07% | -209.88% | -25.33% | 4.13% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 12.61 | -2.66 | -0.16 | -2.80 | 10.60 |
| Price-to-Sales (P/S) Ratio | 0.89 | 0.49 | 0.12 | 0.53 | 1.31 |
| Price-to-Book (P/B) Ratio | 1.27 | 1.05 | 0.19 | 0.43 | 1.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 4.22 | 14.15 | -0.48 | -3.95 | 24.20 |
| Price-to-Operating Cash Flow Ratio | 3.88 | 8.63 | -0.60 | -17.35 | 7.24 |
| Price-to-Earnings Growth (PEG) Ratio | -0.10 | 0.04 | -0.00 | 0.01 | -0.36 |
| Enterprise Value Multiple | 4.32 | 20.29 | -18.54 | 87.61 | 5.20 |
| Enterprise Value | 1.03B | 1.08B | 871.38M | 1.38B | 2.62B |
| EV to EBITDA | 4.32 | 20.29 | -18.54 | 87.61 | 5.20 |
| EV to Sales | 1.38 | 1.04 | 0.83 | 1.23 | 1.48 |
| EV to Free Cash Flow | 6.56 | 30.26 | -3.38 | -9.18 | 27.27 |
| EV to Operating Cash Flow | 6.03 | 18.45 | -4.22 | -40.34 | 8.16 |
| Tangible Book Value Per Share | 1.61 | -0.35 | 1.62 | 8.80 | 14.62 |
| Shareholders’ Equity Per Share | 9.77 | 9.11 | 12.68 | 27.70 | 30.12 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.36 | -0.33 | -0.04 | 0.03 | 0.28 |
| Revenue Per Share | 13.89 | 19.69 | 20.49 | 22.31 | 33.15 |
| Net Income Per Share | 0.98 | -3.60 | -14.85 | -4.22 | 4.10 |
| Tax Burden | 0.64 | 1.33 | 1.04 | 0.97 | 0.72 |
| Interest Burden | 0.58 | 2.74 | 4.35 | 2.00 | 0.79 |
| Research & Development to Revenue | 0.07 | 0.07 | 0.11 | 0.17 | 0.13 |
| SG&A to Revenue | 0.25 | 0.29 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 |
| Income Quality | 3.24 | -0.31 | 0.27 | 0.16 | 1.39 |
Currency in USD
